What is Q32 BIO INC's earnings per share (EPS)?

Q32 BIO INC (QTTB) reported diluted earnings per share of $2.42 for fiscal year 2025. This represents a 136.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Q32 BIO INC Financials

QTTB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Q32 BIO INC (QTTB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 76/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Q32 BIO INC has an operating margin of 31.4%, meaning the company retains $31 of operating profit per $100 of revenue. This strong profitability earns a score of 92/100, reflecting efficient cost management and pricing power.

Leverage

Q32 BIO INC carries a low D/E ratio of 0.47, meaning only $0.47 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.85, Q32 BIO INC holds $4.85 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 97/100.

Cash Flow

While Q32 BIO INC generated -$33.5M in operating cash flow, capex of $0 consumed most of it, leaving -$33.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

100

Q32 BIO INC earns a strong 71.0% return on equity (ROE), meaning it generates $71 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from -841.1% the prior year.

Altman Z-Score Distress

0.81

Q32 BIO INC scores 0.81, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($93.3M) relative to total liabilities ($19.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Weak

3/9

Q32 BIO INC passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

-1.12x

For every $1 of reported earnings, Q32 BIO INC generates $-1.12 in operating cash flow (-$33.5M OCF vs $29.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

16.0x

Q32 BIO INC earns $16.0 in operating income for every $1 of interest expense ($16.9M vs $1.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$53.7M

5Y CAGR+81.9%

Q32 BIO INC generated $53.7M in revenue in fiscal year 2025.

EBITDA

$17.3M

YoY+126.4%

Q32 BIO INC's EBITDA was $17.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 126.4% from the prior year.

Net Income

$29.8M

YoY+162.5%

Q32 BIO INC reported $29.8M in net income in fiscal year 2025. This represents an increase of 162.5% from the prior year.

EPS (Diluted)

$2.42

YoY+136.8%

Q32 BIO INC earned $2.42 per diluted share (EPS) in fiscal year 2025. This represents an increase of 136.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$33.5M

YoY+50.5%

Q32 BIO INC generated -$33.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 50.5% from the prior year.

Cash & Debt

$48.3M

YoY-38.1%

5Y CAGR-26.0%

Q32 BIO INC held $48.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

13M

YoY+5.4%

Q32 BIO INC had 13M shares outstanding in fiscal year 2025. This represents an increase of 5.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

31.4%

5Y CAGR+4852.4pp

Q32 BIO INC's operating margin was 31.4% in fiscal year 2025, reflecting core business profitability.

Net Margin

55.5%

5Y CAGR+4818.4pp

Q32 BIO INC's net profit margin was 55.5% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

71.0%

YoY+912.1pp

5Y CAGR+136.6pp

Q32 BIO INC's ROE was 71.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 912.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$19.2M

YoY-60.2%

5Y CAGR-28.2%

Q32 BIO INC invested $19.2M in research and development in fiscal year 2025. This represents a decrease of 60.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Q32 BIO INC invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

QTTB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$53.7M	$0-100.0%	$1.2M-64.0%	$3.2M-90.6%	$34.0M+1157.3%	$2.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$19.2M-60.2%	$48.1M+51.7%	$31.7M-67.7%	$98.4M+5.7%	$93.1M-7.3%	$100.4M
SG&A Expenses	$17.7M-1.6%	$18.0M+81.9%	$9.9M-74.1%	$38.1M+3.5%	$36.8M+13.1%	$32.6M
Operating Income	$16.9M+125.6%	-$66.1M-37.0%	-$48.3M+63.8%	-$133.3M-38.9%	-$95.9M+26.3%	-$130.3M
Interest Expense	$1.1M-62.7%	$2.8M+88.8%	$1.5M	N/A	N/A	N/A
Income Tax	$0-100.0%	$21K-93.4%	$318K-55.5%	$715K	$0	$0
Net Income	$29.8M+162.5%	-$47.7M+11.2%	-$53.7M-973.8%	-$5.0M+94.8%	-$95.8M+25.6%	-$128.7M
EPS (Diluted)	$2.42+136.8%	$-6.58	$-153.96	$-0.09+94.8%	$-1.73	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$3.6M-31.1%	$5.2M-27.6%	$7.1M	N/A	$14.3M+7.0%	$13.4M+36.3%	$9.8M
SG&A Expenses	N/A	$4.0M+0.3%	$4.0M-21.4%	$5.1M	N/A	$4.5M-0.9%	$4.5M-9.9%	$5.0M
Operating Income	N/A	-$7.6M+17.4%	-$9.2M+25.0%	-$12.2M	N/A	-$18.8M-5.0%	-$17.9M-20.7%	-$14.8M
Interest Expense	N/A	-$220K+22.5%	-$284K+23.5%	-$371K	N/A	-$917K+14.1%	-$1.1M-493.3%	-$180K
Income Tax	N/A	$0	$0	$0	N/A	$0	$0	$0
Net Income	N/A	-$7.4M+22.1%	-$9.5M+14.0%	-$11.0M	N/A	-$17.6M-3.6%	-$17.0M-1750.0%	$1.0M
EPS (Diluted)	N/A	$-0.60+23.1%	$-0.78+13.3%	$-0.90	N/A	$-1.46-2.8%	$-1.42+77.6%	$-6.33

QTTB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$61.8M-33.1%	$92.3M+96.2%	$47.1M-79.4%	$228.5M+7.9%	$211.7M-19.7%	$263.7M
Current Assets	$55.0M-32.8%	$81.9M+185.1%	$28.7M-84.1%	$181.0M-5.7%	$191.9M-12.6%	$219.6M
Cash & Equivalents	$48.3M-38.1%	$78.0M+204.3%	$25.6M-24.6%	$34.0M-68.6%	$108.4M-50.2%	$217.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$19.8M-77.2%	$86.7M-62.3%	$230.0M-36.0%	$359.2M+753.8%	$42.1M-37.9%	$67.7M
Current Liabilities	$11.3M-31.1%	$16.5M+16.7%	$14.1M-37.5%	$22.6M+31.1%	$17.2M-24.0%	$22.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$42.0M+640.3%	$5.7M+103.1%	-$182.9M-39.9%	-$130.7M-177.0%	$169.7M-13.4%	$196.0M
Retained Earnings	-$205.0M+12.7%	-$234.8M-25.5%	-$187.1M+56.4%	-$429.1M-1.2%	-$424.1M-29.2%	-$328.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$61.8M+6.9%	$57.8M-12.6%	$66.1M-16.4%	$79.1M-14.4%	$92.3M-11.7%	$104.5M-15.8%	$124.2M-18.5%	$152.3M
Current Assets	$55.0M+8.3%	$50.8M-12.9%	$58.3M-15.0%	$68.6M-16.2%	$81.9M-12.8%	$93.9M-15.9%	$111.6M-19.1%	$138.0M
Cash & Equivalents	$48.3M-1.5%	$49.0M-10.6%	$54.8M-16.3%	$65.5M-16.0%	$78.0M-12.5%	$89.1M-8.8%	$97.7M-15.5%	$115.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$19.8M-74.1%	$76.2M-2.7%	$78.4M-5.7%	$83.1M-4.1%	$86.7M+0.5%	$86.2M-4.9%	$90.7M-12.4%	$103.6M
Current Liabilities	$11.3M+2.1%	$11.1M-3.7%	$11.5M-20.9%	$14.6M-11.5%	$16.5M+14.5%	$14.4M-16.3%	$17.2M-47.8%	$33.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$42.0M+327.7%	-$18.4M-50.8%	-$12.2M-204.8%	-$4.0M-170.7%	$5.7M-69.0%	$18.3M-45.4%	$33.5M-31.3%	$48.8M
Retained Earnings	-$205.0M+22.0%	-$262.7M-2.9%	-$255.3M-3.9%	-$245.8M-4.7%	-$234.8M-6.4%	-$220.6M-8.7%	-$203.0M-9.1%	-$186.1M

QTTB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$33.5M+50.5%	-$67.7M-262.6%	-$18.7M+83.6%	-$113.7M-3.6%	-$109.8M-16.3%	-$94.3M
Capital Expenditures	$0-100.0%	$75K+1400.0%	$5K-99.6%	$1.3M-46.4%	$2.4M-35.8%	$3.7M
Free Cash Flow	-$33.5M+50.5%	-$67.8M-262.9%	-$18.7M+83.7%	-$114.9M-2.5%	-$112.1M-14.4%	-$98.1M
Investing Cash Flow	$7.0M-64.9%	$19.9M+398600.0%	-$5K-100.0%	$36.7M+172.3%	-$50.8M-124.8%	$204.9M
Financing Cash Flow	-$3.1M-103.3%	$95.1M+23333.0%	$406K-31.9%	$596K-98.9%	$52.2M-1.7%	$53.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$6.2M-46.1%	-$4.2M+60.3%	-$10.7M+14.7%	-$12.5M-9.2%	-$11.4M+41.5%	-$19.5M+12.1%	-$22.2M-52.7%	-$14.6M
Capital Expenditures	$0	$0	N/A	N/A	$2K-96.6%	$58K+286.7%	$15K	$0
Free Cash Flow	-$6.2M-46.1%	-$4.2M	N/A	N/A	-$11.4M+41.6%	-$19.6M+11.9%	-$22.2M-52.8%	-$14.6M
Investing Cash Flow	$7.0M	$0	$0	$0+100.0%	-$2K-100.0%	$9.9M+0.5%	$9.9M+10093.8%	$97K
Financing Cash Flow	-$1.6M+0.1%	-$1.6M	N/A	N/A	$317K-68.2%	$997K+118.1%	-$5.5M-105.6%	$99.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

QTTB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	31.4%	N/A	-4174.3%-19.7pp	-4154.6%-3872.2pp	-282.4%+4538.5pp	-4821.0%
Net Margin	55.5%	N/A	-4649.0%-4493.0pp	-156.0%+125.9pp	-281.9%+4481.0pp	-4762.9%
Return on Equity	71.0%+912.1pp	-841.1%	N/A	N/A	-56.5%+9.2pp	-65.7%
Return on Assets	48.3%+100.0pp	-51.7%+62.5pp	-114.2%-112.0pp	-2.2%+43.0pp	-45.2%+3.6pp	-48.8%
Current Ratio	4.85-0.1	4.97+2.9	2.04-6.0	8.02-3.1	11.14+1.5	9.69
Debt-to-Equity	0.47-14.8	15.27+16.5	-1.26+1.5	-2.75-3.0	0.25-0.1	0.35
FCF Margin	-62.4%	N/A	-1616.1%+1967.0pp	-3583.1%-3253.0pp	-330.1%+3299.2pp	-3629.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-96.2%-45.5pp	-50.7%-52.8pp	2.1%
Return on Assets	N/A	-12.8%+1.6pp	-14.3%-0.4pp	-14.0%	N/A	-16.8%-3.2pp	-13.7%-14.3pp	0.7%
Current Ratio	4.85+0.3	4.57-0.5	5.06+0.3	4.71-0.3	4.97-1.6	6.53+0.0	6.49+2.3	4.19
Debt-to-Equity	0.47+4.6	-4.13+2.3	-6.40+14.3	-20.70-36.0	15.27+10.6	4.71+2.0	2.71+0.6	2.12
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Akari Therapeutics Plc AKTX

$5.1M

Lixte Biotechnology Hldgs Inc LIXT

$26.5M

SAB BIOTHERAPEUTICS INC SABS

$272.7M

Curis CRIS

$22.0M

Exicure Inc XCUR

$26.7M

Frequently Asked Questions

What is Q32 BIO INC's annual revenue?

Q32 BIO INC (QTTB) reported $53.7M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Q32 BIO INC profitable?

Yes, Q32 BIO INC (QTTB) reported a net income of $29.8M in fiscal year 2025, with a net profit margin of 55.5%.

What is Q32 BIO INC's EBITDA?

Q32 BIO INC (QTTB) had EBITDA of $17.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Q32 BIO INC's operating margin?

Q32 BIO INC (QTTB) had an operating margin of 31.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Q32 BIO INC's net profit margin?

Q32 BIO INC (QTTB) had a net profit margin of 55.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Q32 BIO INC's return on equity (ROE)?

Q32 BIO INC (QTTB) has a return on equity of 71.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Q32 BIO INC's free cash flow?

Q32 BIO INC (QTTB) generated -$33.5M in free cash flow during fiscal year 2025. This represents a 50.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Q32 BIO INC's operating cash flow?

Q32 BIO INC (QTTB) generated -$33.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Q32 BIO INC's total assets?

Q32 BIO INC (QTTB) had $61.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Q32 BIO INC's capital expenditures?

Q32 BIO INC (QTTB) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Q32 BIO INC spend on research and development?

Q32 BIO INC (QTTB) invested $19.2M in research and development during fiscal year 2025.

How many shares does Q32 BIO INC have outstanding?

Q32 BIO INC (QTTB) had 13M shares outstanding as of fiscal year 2025.

What is Q32 BIO INC's current ratio?

Q32 BIO INC (QTTB) had a current ratio of 4.85 as of fiscal year 2025, which is generally considered healthy.

What is Q32 BIO INC's debt-to-equity ratio?

Q32 BIO INC (QTTB) had a debt-to-equity ratio of 0.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Q32 BIO INC's return on assets (ROA)?

Q32 BIO INC (QTTB) had a return on assets of 48.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Q32 BIO INC's cash runway?

Based on fiscal year 2025 data, Q32 BIO INC (QTTB) had $48.3M in cash against an annual operating cash burn of $33.5M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Q32 BIO INC's Altman Z-Score?

Q32 BIO INC (QTTB) has an Altman Z-Score of 0.81, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Q32 BIO INC's Piotroski F-Score?

Q32 BIO INC (QTTB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Q32 BIO INC's earnings high quality?

Q32 BIO INC (QTTB) has an earnings quality ratio of -1.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Q32 BIO INC cover its interest payments?

Q32 BIO INC (QTTB) has an interest coverage ratio of 16.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Q32 BIO INC?

Q32 BIO INC (QTTB) scores 76 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.